The joint pain injections market is a rapidly growing segment of the orthopedic therapeutics industry owing to the growing geriatric population and increasing prevalence of joint disorders like osteoarthritis. Joint pain injections are used to treat various types of joint and muscle pain. They involve direct injection of medications like corticosteroids, hyaluronic acid or platelet-rich plasma into the joints or surrounding tissues to relieve pain and inflammation.

Joint pain is a common problem faced by a large population worldwide due to joint disorders, injuries or aging. Injections are frequently used to manage joint pain as they provide fast and targeted relief from pain and swelling.

The global joint pain injections market is estimated to be valued at US$ 9.46 Bn in 2024 and is expected to exhibit a CAGR of 8.7% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Joint Pain Injections Market Growth  are Pfizer, Inc., Ferring Pharmaceuticals Inc., PACIRA BIOSCIENCES, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Sanofi, Anika Therapeutics, Inc., Bioventus, Dr. Reddy’s Laboratories Ltd., Zimmer Biomet, Ferring B.V., SEIKAGAKU CORPORATION, and Ono Pharmaceutical Co., Ltd. The increasing geriatric population suffering from joint disorders like osteoarthritis is driving the growth of key players in the market.

The rising prevalence of joint disorders due to sedentary lifestyles and obesity has resulted in a growing demand for joint pain relief treatments. According to studies, over 30 million Americans suffer from arthritis or joint disorders. Non-invasive treatment options like injections are gaining popularity over surgeries due to their convenience and effectiveness in managing joint pain.

Technological advancements are expanding the product portfolio in the joint pain injections market. New drug formulations that offer longer relief from pain with minimal side effects are being introduced. Combination therapies using platelet-rich plasma along with corticosteroids or hyaluronic acid are proving more effective than single therapies for treating osteoarthritis.

Market Trends

Growing preference for biologics: With advances in biotechnology, novel biologic joint pain therapies like platelet rich plasma and stem cell therapies are emerging trends in pain management. Their natural compositions make them safer alternatives to chemical drugs.

Personalized treatment approaches: With a better understanding of disease pathology, tailored treatment plans are being designed using various injections based on individual patient factors like severity and type of joint disorder. This shift towards personalized care delivery is an important trend.

Market Opportunities

Emerging economies: Developing nations are expected to present lucrative opportunities for market players due to rising healthcare investments, increasing disease burden and growing medical tourism.

Combination therapies: Combining different classes of drugs and biologics can achieve synergistic pain relief effects. Investment in clinical trials of combination regimens holds promise.

Impact of COVID-19 on Joint Pain Injections Market Growth
The COVID-19 pandemic has impacted the growth of the joint pain injections market. During the initial outbreak of the virus, there was a decline in the number of surgeries and procedures performed which reduced the demand for joint pain injections. Lockdowns and restrictions imposed by various governments made it difficult for people to visit hospitals and clinics for treatment. With healthcare resources diverted towards managing COVID-19 patients, elective procedures were postponed which affected the market negatively. However, as restrictions are being lifted gradually, the market is recovering. The demand for pain management treatments is increasing again as people start focusing on non-COVID healthcare needs. Manufacturers are restarting their production activities to cater to the growing requirements. Teleconsultations have also emerged as an alternative for patients to seek advice from doctors during this time. In the coming years, as vaccination programmes lead to normalization, the joint pain injections market is expected to regain its pre-COVID growth trajectory. Players would need to ensure supply chain resilience and optimize production to meet future demand spikes efficiently.

In terms of geographical regions, North America accounted for the largest share of the joint pain injections market in terms of value owing to the rising prevalence of osteoarthritis and musculoskeletal disorders. Availability of advanced healthcare infrastructure and reimbursement policies have boosted procedures related to joint injections in the US and Canada. Within Asia Pacific, China currently holds the largest market for joint pain injections due to growing medical tourism and increasing focus of players to tap the opportunities in this region. With rising geriatric population and investments in healthcare, China is expected to be the fastest growing regional market for joint pain injections during the forecast period. Players would need to establish local manufacturing and distribution networks to efficiently cater to the Chinese market.

Get More Insights On This Topic: Joint Pain Injections Market